National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Olaparib ( Lynparza®) adjuvant treatment of early breast cancer. HTA ID:22065.

Olaparib is indicated as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 26/10/2022
Rapid review completed 20/10/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 26/10/2022
Pre-submission consultation with Applicant Scheduled
Current Status Pre-submission consultation Scheduled